GSK slides after Q1 update as investors focus on outlook, FX headwinds, and one-off vaccine strength

GSK plc (GSK) is down 7.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The decline appears tied to the market’s reaction to GSK’s first-quarter update: results showed strength in key products (notably shingles vaccine sales), but investors seemed to focus on the quality and durability of the beat, with currency and outlook-related caveats tempering enthusiasm. With full-year guidance largely reiterated, the stock move suggests expectations may have been higher into the print.

Details:

GSK reported a solid start to 2026 and kept its 2026 outlook in place, but highlighted that foreign-exchange dynamics can weigh on reported results versus constant-currency performance.

Shingrix sales were strong in the quarter, helped by channel inventory dynamics (pharmacies and hospitals stocking up), which can be viewed as non-recurring versus steady end-demand.

General Medicines revenue declined year over year, while certain mature brands and payer dynamics remained a watch item alongside mixed growth across the portfolio.

Management pointed to multiple pipeline milestones expected later in 2026, which may shift near-term attention away from the quarter and toward upcoming readouts and approvals.

Sources:

GSK, Associated Press, WTAQ

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive GSK Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$GSK Hedge Fund Activity

We have seen 420 institutional investors add shares of $GSK stock to their portfolio, and 435 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DODGE & COX removed 9,885,765 shares (-12.6%) from their portfolio in Q4 2025, for an estimated $484,797,915
WELLINGTON MANAGEMENT GROUP LLP added 9,137,167 shares (+267.1%) to their portfolio in Q4 2025, for an estimated $448,086,669
ACADIAN ASSET MANAGEMENT LLC added 6,175,701 shares (+221.5%) to their portfolio in Q4 2025, for an estimated $302,856,377
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 2,265,186 shares (+inf%) to their portfolio in Q4 2025, for an estimated $111,084,721
CAPITAL RESEARCH GLOBAL INVESTORS removed 1,794,427 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $87,998,700
UBS GROUP AG added 1,635,448 shares (+35.2%) to their portfolio in Q4 2025, for an estimated $80,202,369
POINT72 ASSET MANAGEMENT, L.P. added 1,474,951 shares (+inf%) to their portfolio in Q4 2025, for an estimated $72,331,597

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$GSK Congressional Stock Trading

Members of Congress have traded $GSK stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $GSK stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$GSK Analyst Ratings

Wall Street analysts have issued reports on $GSK in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Underweight" rating on 01/06/2026

To track analyst ratings and price targets for $GSK, check out Quiver Quantitative's $GSK forecast page.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.